Skip to main content

Table 2 PPH outcomes by study group*

From: Testing a home-based model of care using misoprostol for prevention and treatment of postpartum hemorrhage: results from a randomized placebo-controlled trial conducted in Badakhshan province, Afghanistan

 Misoprostol
(800mcg SL)
(n = 40)
Placebo
(n = 39)
RR 95% CIP value
Primary outcome
 Hb drop ≥2 g/dL a22 (56.4)20 (60.6)0.93 (0.61, 1.45)0.45
Secondary outcomes
 Post-delivery Hb (g/dL), mean ± SD b10 ± 1.79.9 ± 1.7 0.94
 Postpartum Hb ≤ 8 g/dL b7 (17.5)8 (21.1)0.83 (0.29, 2.33)0.78
 Pre to post-delivery Hb drop (g/dL), mean ± SD a2.4 ± 1.52.4 ± 1.8 0.99
 Hb drop ≥3 g/dL a13 (33.3)12 (36.4)0.92 (0.45, 1.89)0.81
 Transferred to facility from home18 (45.0)15 (38.5)1.17 (0.66, 2.11)0.56
 Administered IV oxytocin at facility17 (42.5)14 (35.9)1.18 (0.64, 2.21)0.55
Other interventions (Ns listed):
 Administered ergometrine26  
 Manual removal of placenta21  
 Suturing/tear repair11  
 Hysterectomy/other surgery00  
  1. Abbreviations: Hb hemoglobin, SL sublingual, RR relative risk, CI confidence interval
  2. * Data presented as n (%) unless otherwise stated
  3. a Pre and post Hb measures available for n = 39 in the misoprostol arm and n = 33 in the placebo arm
  4. b In one case (placebo) no post-delivery Hb was available for the one maternal death